| 卞晓山,王秀问,魏长宏,等.吉西他滨或多西他赛联合卡铂治疗60岁以下晚期肺鳞癌疗效及预后追踪分析[J].安徽医药,2016,20(1):167-170. |
| 吉西他滨或多西他赛联合卡铂治疗60岁以下晚期肺鳞癌疗效及预后追踪分析 |
| Efficacy of gemcitabine or docetaxel combined with carboplatin in treatment of advanced lung squamous cell carcinoma patients under 60 years old and prognosis trace analysis |
| 投稿时间：2015-09-09 |
| DOI： |
| 中文关键词: 肺鳞癌 吉西他滨 多西他赛 预后 |
| 英文关键词: squamous cell lung carcinoma gemcitabine docetaxel prognosis |
| 基金项目:上海优秀青年教师扶助基金项目(No B010310009；上海市科委重点科技攻关项目(No 11DZ1972003) |
|
| 摘要点击次数: 2692 |
| 全文下载次数: 102 |
| 中文摘要: |
| 目的 探讨吉西他滨或多西他赛联合卡铂治疗60岁以下晚期肺鳞癌疗效,以及对预后的影响。方法 91例60岁以下初治晚期肺鳞癌患者随机分为吉西他滨联合卡铂组(GC组,n=44)和多西他赛联合卡铂组(DC组,n=47),GC组患者第1天和第8天分别给予1 000 mg·m-2吉西他滨静脉滴注,第1天卡铂AUC=5剂量静脉滴注；DC组患者第1d给予75 mg·m-2多西他赛静脉滴注,第1d卡铂AUC=5剂量静脉滴注。记录两组患者临床疗效、毒副反应及生存质量情况,利用Kaplan-Meier法对患者生存时间进行分析。结果 GC组患者总有效率38.6%,DC组总有效率40.0%,两组相比差异无统计学意义(P>0.05)；两组患者恶心呕吐、肝功能异常发生率差异无统计学意义(P>0.05),两组患者贫血发生率差异无统计学意义(P>0.05),GC组血小板减少发生率和粒细胞减少发生率均高于DC组,差异均有统计学意义(P<0.05),但GC组Ⅲ～Ⅳ级粒细胞减少发生率15.9%,与DC组的8.5%,差异无统计学意义(P>0.05)；两组患者治疗后生存质量各项得分均较治疗前得分提高,尤其是咳嗽、疼痛得分显著提高；GC组患者中位生存时间14.5个月,1年生存率52.7%,2年生存率19.6%；DC组患者中位生存时间11.2个月,1年生存率44.6%,2年生存率11.9%,经Log-rank检验,两组患者生存时间差异有统计学意义(χ2=4.634,P<0.05)。结论 吉西他滨或多西他赛联合卡铂用于60岁以下晚期肺鳞癌患者,总体临床疗效及在改善患者生存质量方面相当,但吉西他滨联合卡铂更有利于延长患者生存时间。 |
| 英文摘要: |
| Objective To explore the efficacy of gemcitabine or docetaxel combined with carboplatin in treatment of advanced lung squamous cell carcinoma patients under 60 years old and the impact on prognosis.Methods A total of 91 cases of advanced lung squamous cell carcinoma patients under 60 years old previously untreated were randomized into gemcitabine combined with carboplatin group (GC group, n=44) and docetaxel combined with carboplatin group (DC group, n=47). Patients in GC group were given 1 000 mg·m-2 gemcitabine intravenous infusion at 1 d and 8 d, and carboplatin AUC=5 dose intravenous infusion. Patients in DC group were given 75 mg·m-2 docetaxel intravenously at 1d, and carboplatin AUC=5 dose intravenous infusion. The clinical efficacy, toxicity and quality of life of the two groups were recorded. The survival spans of patients were analyzed by using Kaplan-Meier method. Results The total efficiency rates of GC group and the DC group were 38.6% and 40.0%, with no significant difference (P>0.05). The differences in incidences of nausea and vomiting and abnormal liver function between the two groups were no significant (P>0.05). The differences of incidences of anemia between the two groups were no significant (P>0.05). The incidences of thrombocytopenia and neutropenia in GC group were higher than the DC group with significant differences(P<0.05). But the incidence of Ⅲ~Ⅳ grade neutropenia in GC group was 15.9% with no significant difference from the DC group (8.5%, P>0.05). The scores of quality of life after treatment in the two groups were higher than before treatment, of which the scores of cough and pain improved significantly. In GC group, the median survival time was 14.5 months, 1-year survival rate 52.7% and 2-year survival rate 19.6%. In DC group, the median survival time was 11.2 months, 1-year survival rate 44.6% and 2-year survival rate 11.9%. By Log-rank test, the differences in survival time between the two groups were statistically significant (χ2=4.634, P<0.05). Conclusion As for gemcitabine or docetaxel combined with carboplatin in treatment of advanced lung squamous cell carcinoma patients under 60-year-old, the overall clinical efficacy and the improved quality of life were similar. But gemcitabine combined with carboplatin was more conducive to prolong the survival time of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
